http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 13 Mar 2026 06:01:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Vaxart%2C+Inc.++++++++++++++For%3A+Dec+31/26155830.html si-local-file:///var/storage/secattach/20260313/26155830.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Vaxart%2C+Inc.++++++++++++++For%3A+Dec+31/26155830.html Fri, 13 Mar 2026 06:01:00 -0400 O.20329759 VXRT http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Vaxart%2C+Inc.++++++++++++++For%3A+Dec+31/26155830.html si-local-file:///var/storage/secattach/20260313/26155830.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Vaxart%2C+Inc.++++++++++++++For%3A+Dec+31/26155830.html Fri, 13 Mar 2026 06:01:00 -0400 O.20329759 VXRT http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Mar+12/26153198.html si-local-file:///var/storage/secattach/20260312/26153198.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Mar+12/26153198.html Thu, 12 Mar 2026 16:12:00 -0400 O.20329759 VXRT http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Mar+12/26153198.html si-local-file:///var/storage/secattach/20260312/26153198.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Mar+12/26153198.html Thu, 12 Mar 2026 16:12:00 -0400 O.20329759 VXRT http://www.streetinsider.com/Press+Releases/Vaxart+Provides+Business+Update+and+Reports+Full+Year+2025+Financial+Results/26152923.html <p align="center"><em>Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated early Q2 2026</em></p> <p align="center"><em>Published positive clinical results in the first quarter of 2026 demonstrating oral norovirus vaccine candidate was safe and immunogenic in lactating women and resulted in passive transfer of antibodies to their infants via breast milk</em></p> <p align="center"><em>Cash, cash equivalents and investments of $63.8 million as of December 31, 2025; Runway into second quarter of 2027</em></p> <p align="center"><em>Conference call today at 4:30 p.m. ET</em></p> <p align="center"><em>Live stockholder fireside chat scheduled for March 13, 2026 at 4:30 p.m. ET</em></p> http://www.streetinsider.com/Press+Releases/Vaxart+Provides+Business+Update+and+Reports+Full+Year+2025+Financial+Results/26152923.html Thu, 12 Mar 2026 16:05:00 -0400 A.42665875 O.14901680 O.20329759 VXRT VXRT http://www.streetinsider.com/Press+Releases/Vaxart+Provides+Business+Update+and+Reports+Full+Year+2025+Financial+Results/26152923.html <p align="center"><em>Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated early Q2 2026</em></p> <p align="center"><em>Published positive clinical results in the first quarter of 2026 demonstrating oral norovirus vaccine candidate was safe and immunogenic in lactating women and resulted in passive transfer of antibodies to their infants via breast milk</em></p> <p align="center"><em>Cash, cash equivalents and investments of $63.8 million as of December 31, 2025; Runway into second quarter of 2027</em></p> <p align="center"><em>Conference call today at 4:30 p.m. ET</em></p> <p align="center"><em>Live stockholder fireside chat scheduled for March 13, 2026 at 4:30 p.m. ET</em></p> http://www.streetinsider.com/Press+Releases/Vaxart+Provides+Business+Update+and+Reports+Full+Year+2025+Financial+Results/26152923.html Thu, 12 Mar 2026 16:05:00 -0400 A.42665875 O.14901680 O.20329759 VXRT VXRT http://www.streetinsider.com/Press+Releases/Vaxart+Provides+Business+Update+and+Reports+Full+Year+2025+Financial+Results/26152923.html <p align="center"><em>Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated early Q2 2026</em></p> <p align="center"><em>Published positive clinical results in the first quarter of 2026 demonstrating oral norovirus vaccine candidate was safe and immunogenic in lactating women and resulted in passive transfer of antibodies to their infants via breast milk</em></p> <p align="center"><em>Cash, cash equivalents and investments of $63.8 million as of December 31, 2025; Runway into second quarter of 2027</em></p> <p align="center"><em>Conference call today at 4:30 p.m. ET</em></p> <p align="center"><em>Live stockholder fireside chat scheduled for March 13, 2026 at 4:30 p.m. ET</em></p> http://www.streetinsider.com/Press+Releases/Vaxart+Provides+Business+Update+and+Reports+Full+Year+2025+Financial+Results/26152923.html Thu, 12 Mar 2026 16:05:00 -0400 A.42665875 O.14901680 O.20329759 VXRT VXRT http://www.streetinsider.com/Press+Releases/Vaxart+Provides+Business+Update+and+Reports+Full+Year+2025+Financial+Results/26152923.html <p align="center"><em>Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated early Q2 2026</em></p> <p align="center"><em>Published positive clinical results in the first quarter of 2026 demonstrating oral norovirus vaccine candidate was safe and immunogenic in lactating women and resulted in passive transfer of antibodies to their infants via breast milk</em></p> <p align="center"><em>Cash, cash equivalents and investments of $63.8 million as of December 31, 2025; Runway into second quarter of 2027</em></p> <p align="center"><em>Conference call today at 4:30 p.m. ET</em></p> <p align="center"><em>Live stockholder fireside chat scheduled for March 13, 2026 at 4:30 p.m. ET</em></p> http://www.streetinsider.com/Press+Releases/Vaxart+Provides+Business+Update+and+Reports+Full+Year+2025+Financial+Results/26152923.html Thu, 12 Mar 2026 16:05:00 -0400 A.42665875 O.14901680 O.20329759 VXRT VXRT http://www.streetinsider.com/Press+Releases/Vaxart+Provides+Business+Update+and+Reports+Full+Year+2025+Financial+Results/26152923.html <p align="center"><em>Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated early Q2 2026</em></p> <p align="center"><em>Published positive clinical results in the first quarter of 2026 demonstrating oral norovirus vaccine candidate was safe and immunogenic in lactating women and resulted in passive transfer of antibodies to their infants via breast milk</em></p> <p align="center"><em>Cash, cash equivalents and investments of $63.8 million as of December 31, 2025; Runway into second quarter of 2027</em></p> <p align="center"><em>Conference call today at 4:30 p.m. ET</em></p> <p align="center"><em>Live stockholder fireside chat scheduled for March 13, 2026 at 4:30 p.m. ET</em></p> http://www.streetinsider.com/Press+Releases/Vaxart+Provides+Business+Update+and+Reports+Full+Year+2025+Financial+Results/26152923.html Thu, 12 Mar 2026 16:05:00 -0400 A.42665875 O.14901680 O.20329759 VXRT VXRT http://www.streetinsider.com/Globe+Newswire/Vaxart+Provides+Business+Update+and+Reports+Full+Year+2025+Financial+Results/26152923.html <p align="center"><em>Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated early Q2 2026</em></p> <p align="center"><em>Published positive clinical results in the first quarter of 2026 demonstrating oral norovirus vaccine candidate was safe and immunogenic in lactating women and resulted in passive transfer of antibodies to their infants via breast milk</em></p> <p align="center"><em>Cash, cash equivalents and investments of $63.8 million as of December 31, 2025; Runway into second quarter of 2027</em></p> <p align="center"><em>Conference call today at 4:30 p.m. ET</em></p> <p align="center"><em>Live stockholder fireside chat scheduled for March 13, 2026 at 4:30 p.m. ET</em></p> http://www.streetinsider.com/Globe+Newswire/Vaxart+Provides+Business+Update+and+Reports+Full+Year+2025+Financial+Results/26152923.html Thu, 12 Mar 2026 16:05:00 -0400 A.42665875 O.14901680 O.20329759 VXRT VXRT http://www.streetinsider.com/Globe+Newswire/Vaxart+Provides+Business+Update+and+Reports+Full+Year+2025+Financial+Results/26152923.html <p align="center"><em>Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated early Q2 2026</em></p> <p align="center"><em>Published positive clinical results in the first quarter of 2026 demonstrating oral norovirus vaccine candidate was safe and immunogenic in lactating women and resulted in passive transfer of antibodies to their infants via breast milk</em></p> <p align="center"><em>Cash, cash equivalents and investments of $63.8 million as of December 31, 2025; Runway into second quarter of 2027</em></p> <p align="center"><em>Conference call today at 4:30 p.m. ET</em></p> <p align="center"><em>Live stockholder fireside chat scheduled for March 13, 2026 at 4:30 p.m. ET</em></p> http://www.streetinsider.com/Globe+Newswire/Vaxart+Provides+Business+Update+and+Reports+Full+Year+2025+Financial+Results/26152923.html Thu, 12 Mar 2026 16:05:00 -0400 A.42665875 O.14901680 O.20329759 VXRT VXRT http://www.streetinsider.com/Globe+Newswire/Vaxart+Provides+Business+Update+and+Reports+Full+Year+2025+Financial+Results/26152923.html <p align="center"><em>Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated early Q2 2026</em></p> <p align="center"><em>Published positive clinical results in the first quarter of 2026 demonstrating oral norovirus vaccine candidate was safe and immunogenic in lactating women and resulted in passive transfer of antibodies to their infants via breast milk</em></p> <p align="center"><em>Cash, cash equivalents and investments of $63.8 million as of December 31, 2025; Runway into second quarter of 2027</em></p> <p align="center"><em>Conference call today at 4:30 p.m. ET</em></p> <p align="center"><em>Live stockholder fireside chat scheduled for March 13, 2026 at 4:30 p.m. ET</em></p> http://www.streetinsider.com/Globe+Newswire/Vaxart+Provides+Business+Update+and+Reports+Full+Year+2025+Financial+Results/26152923.html Thu, 12 Mar 2026 16:05:00 -0400 A.42665875 O.14901680 O.20329759 VXRT VXRT http://www.streetinsider.com/Globe+Newswire/Vaxart+Provides+Business+Update+and+Reports+Full+Year+2025+Financial+Results/26152923.html <p align="center"><em>Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated early Q2 2026</em></p> <p align="center"><em>Published positive clinical results in the first quarter of 2026 demonstrating oral norovirus vaccine candidate was safe and immunogenic in lactating women and resulted in passive transfer of antibodies to their infants via breast milk</em></p> <p align="center"><em>Cash, cash equivalents and investments of $63.8 million as of December 31, 2025; Runway into second quarter of 2027</em></p> <p align="center"><em>Conference call today at 4:30 p.m. ET</em></p> <p align="center"><em>Live stockholder fireside chat scheduled for March 13, 2026 at 4:30 p.m. ET</em></p> http://www.streetinsider.com/Globe+Newswire/Vaxart+Provides+Business+Update+and+Reports+Full+Year+2025+Financial+Results/26152923.html Thu, 12 Mar 2026 16:05:00 -0400 A.42665875 O.14901680 O.20329759 VXRT VXRT http://www.streetinsider.com/Globe+Newswire/Vaxart+Provides+Business+Update+and+Reports+Full+Year+2025+Financial+Results/26152923.html <p align="center"><em>Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated early Q2 2026</em></p> <p align="center"><em>Published positive clinical results in the first quarter of 2026 demonstrating oral norovirus vaccine candidate was safe and immunogenic in lactating women and resulted in passive transfer of antibodies to their infants via breast milk</em></p> <p align="center"><em>Cash, cash equivalents and investments of $63.8 million as of December 31, 2025; Runway into second quarter of 2027</em></p> <p align="center"><em>Conference call today at 4:30 p.m. ET</em></p> <p align="center"><em>Live stockholder fireside chat scheduled for March 13, 2026 at 4:30 p.m. ET</em></p> http://www.streetinsider.com/Globe+Newswire/Vaxart+Provides+Business+Update+and+Reports+Full+Year+2025+Financial+Results/26152923.html Thu, 12 Mar 2026 16:05:00 -0400 A.42665875 O.14901680 O.20329759 VXRT VXRT http://www.streetinsider.com/Press+Releases/Vaxart+to+Host+Upcoming+Conference+Calls/26101019.html <p align="center"><em>Full year 2025 business update and financial results conference call to be held March 12 at 4:30 p.m. ET</em></p> <p align="center"><em>Stockholder fireside chat to be held on March 13 at 4:30 p.m. ET</em></p> <p>SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will host two upcoming webcast conference calls.</p> <p><strong><em>Full Year 2025 Business Update and Financial Results</em></strong><br/>Vaxart will provide a business update and report financial results for the full year ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Vaxart senior management team will http://www.streetinsider.com/Press+Releases/Vaxart+to+Host+Upcoming+Conference+Calls/26101019.html Tue, 03 Mar 2026 16:01:00 -0400 A.42665875 O.14901680 O.20329759 VXRT VXRT http://www.streetinsider.com/Press+Releases/Vaxart+to+Host+Upcoming+Conference+Calls/26101019.html <p align="center"><em>Full year 2025 business update and financial results conference call to be held March 12 at 4:30 p.m. ET</em></p> <p align="center"><em>Stockholder fireside chat to be held on March 13 at 4:30 p.m. ET</em></p> <p>SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will host two upcoming webcast conference calls.</p> <p><strong><em>Full Year 2025 Business Update and Financial Results</em></strong><br/>Vaxart will provide a business update and report financial results for the full year ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Vaxart senior management team will http://www.streetinsider.com/Press+Releases/Vaxart+to+Host+Upcoming+Conference+Calls/26101019.html Tue, 03 Mar 2026 16:01:00 -0400 A.42665875 O.14901680 O.20329759 VXRT VXRT http://www.streetinsider.com/Press+Releases/Vaxart+to+Host+Upcoming+Conference+Calls/26101019.html <p align="center"><em>Full year 2025 business update and financial results conference call to be held March 12 at 4:30 p.m. ET</em></p> <p align="center"><em>Stockholder fireside chat to be held on March 13 at 4:30 p.m. ET</em></p> <p>SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will host two upcoming webcast conference calls.</p> <p><strong><em>Full Year 2025 Business Update and Financial Results</em></strong><br/>Vaxart will provide a business update and report financial results for the full year ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Vaxart senior management team will http://www.streetinsider.com/Press+Releases/Vaxart+to+Host+Upcoming+Conference+Calls/26101019.html Tue, 03 Mar 2026 16:01:00 -0400 A.42665875 O.14901680 O.20329759 VXRT VXRT http://www.streetinsider.com/Press+Releases/Vaxart+to+Host+Upcoming+Conference+Calls/26101019.html <p align="center"><em>Full year 2025 business update and financial results conference call to be held March 12 at 4:30 p.m. ET</em></p> <p align="center"><em>Stockholder fireside chat to be held on March 13 at 4:30 p.m. ET</em></p> <p>SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will host two upcoming webcast conference calls.</p> <p><strong><em>Full Year 2025 Business Update and Financial Results</em></strong><br/>Vaxart will provide a business update and report financial results for the full year ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Vaxart senior management team will http://www.streetinsider.com/Press+Releases/Vaxart+to+Host+Upcoming+Conference+Calls/26101019.html Tue, 03 Mar 2026 16:01:00 -0400 A.42665875 O.14901680 O.20329759 VXRT VXRT http://www.streetinsider.com/Press+Releases/Vaxart+to+Host+Upcoming+Conference+Calls/26101019.html <p align="center"><em>Full year 2025 business update and financial results conference call to be held March 12 at 4:30 p.m. ET</em></p> <p align="center"><em>Stockholder fireside chat to be held on March 13 at 4:30 p.m. ET</em></p> <p>SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will host two upcoming webcast conference calls.</p> <p><strong><em>Full Year 2025 Business Update and Financial Results</em></strong><br/>Vaxart will provide a business update and report financial results for the full year ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Vaxart senior management team will http://www.streetinsider.com/Press+Releases/Vaxart+to+Host+Upcoming+Conference+Calls/26101019.html Tue, 03 Mar 2026 16:01:00 -0400 A.42665875 O.14901680 O.20329759 VXRT VXRT http://www.streetinsider.com/Globe+Newswire/Vaxart+to+Host+Upcoming+Conference+Calls/26101019.html <p align="center"><em>Full year 2025 business update and financial results conference call to be held March 12 at 4:30 p.m. ET</em></p> <p align="center"><em>Stockholder fireside chat to be held on March 13 at 4:30 p.m. ET</em></p> <p>SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will host two upcoming webcast conference calls.</p> <p><strong><em>Full Year 2025 Business Update and Financial Results</em></strong><br/>Vaxart will provide a business update and report financial results for the full year ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Vaxart senior management team will http://www.streetinsider.com/Globe+Newswire/Vaxart+to+Host+Upcoming+Conference+Calls/26101019.html Tue, 03 Mar 2026 16:01:00 -0400 A.42665875 O.14901680 O.20329759 VXRT VXRT http://www.streetinsider.com/Globe+Newswire/Vaxart+to+Host+Upcoming+Conference+Calls/26101019.html <p align="center"><em>Full year 2025 business update and financial results conference call to be held March 12 at 4:30 p.m. ET</em></p> <p align="center"><em>Stockholder fireside chat to be held on March 13 at 4:30 p.m. ET</em></p> <p>SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will host two upcoming webcast conference calls.</p> <p><strong><em>Full Year 2025 Business Update and Financial Results</em></strong><br/>Vaxart will provide a business update and report financial results for the full year ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Vaxart senior management team will http://www.streetinsider.com/Globe+Newswire/Vaxart+to+Host+Upcoming+Conference+Calls/26101019.html Tue, 03 Mar 2026 16:01:00 -0400 A.42665875 O.14901680 O.20329759 VXRT VXRT http://www.streetinsider.com/Globe+Newswire/Vaxart+to+Host+Upcoming+Conference+Calls/26101019.html <p align="center"><em>Full year 2025 business update and financial results conference call to be held March 12 at 4:30 p.m. ET</em></p> <p align="center"><em>Stockholder fireside chat to be held on March 13 at 4:30 p.m. ET</em></p> <p>SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will host two upcoming webcast conference calls.</p> <p><strong><em>Full Year 2025 Business Update and Financial Results</em></strong><br/>Vaxart will provide a business update and report financial results for the full year ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Vaxart senior management team will http://www.streetinsider.com/Globe+Newswire/Vaxart+to+Host+Upcoming+Conference+Calls/26101019.html Tue, 03 Mar 2026 16:01:00 -0400 A.42665875 O.14901680 O.20329759 VXRT VXRT http://www.streetinsider.com/Globe+Newswire/Vaxart+to+Host+Upcoming+Conference+Calls/26101019.html <p align="center"><em>Full year 2025 business update and financial results conference call to be held March 12 at 4:30 p.m. ET</em></p> <p align="center"><em>Stockholder fireside chat to be held on March 13 at 4:30 p.m. ET</em></p> <p>SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will host two upcoming webcast conference calls.</p> <p><strong><em>Full Year 2025 Business Update and Financial Results</em></strong><br/>Vaxart will provide a business update and report financial results for the full year ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Vaxart senior management team will http://www.streetinsider.com/Globe+Newswire/Vaxart+to+Host+Upcoming+Conference+Calls/26101019.html Tue, 03 Mar 2026 16:01:00 -0400 A.42665875 O.14901680 O.20329759 VXRT VXRT http://www.streetinsider.com/Globe+Newswire/Vaxart+to+Host+Upcoming+Conference+Calls/26101019.html <p align="center"><em>Full year 2025 business update and financial results conference call to be held March 12 at 4:30 p.m. ET</em></p> <p align="center"><em>Stockholder fireside chat to be held on March 13 at 4:30 p.m. ET</em></p> <p>SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will host two upcoming webcast conference calls.</p> <p><strong><em>Full Year 2025 Business Update and Financial Results</em></strong><br/>Vaxart will provide a business update and report financial results for the full year ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Vaxart senior management team will http://www.streetinsider.com/Globe+Newswire/Vaxart+to+Host+Upcoming+Conference+Calls/26101019.html Tue, 03 Mar 2026 16:01:00 -0400 A.42665875 O.14901680 O.20329759 VXRT VXRT http://www.streetinsider.com/Press+Releases/Vaxart+to+Present+at+the+Oppenheimer+36th+Annual+Healthcare+Life+Sciences+Conference+on+February+25%2C+2026/26018235.html <p>SOUTH SAN FRANCISCO, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral vaccines based on its proprietary delivery platform, today announced that members of the management team will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference taking place virtually February 25-26, 2026.</p> <p align="justify"><strong>Presentation Details:</strong></p> <p align="justify"><strong>Date and Time:</strong> Wednesday, February 25 at 4:00pm ET<br/><strong>Registration and Webcast:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=6WJNy2u-EracmuHlmpwRqN7mY1ch9cyt0eJjjrydaXHs4dTUJgqR2mwz-yyz7w62-j5OQ9FWMQ4GJ-rI773eI1ifx2IgEbnCbkUMtvT3LrBT3p_tHhR66DD27dLrk9rgkgXbNVz-pMAVWOFkd6DbZGfzweoEZ-6RfUHRfkYXOzgiAE4oOo-et5xO6kZLRgVy" rel="nofollow" target="_blank">Click Here</a></p> <p>The webcast will be available on the Company’s investor relations website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=yW4bxEPt6YNcuyM2zDleGz3vajU3hbNMkr8fjlb0MOmA1lGVTkk310oatqjRZ0zdLgLXlmYZUw7OQLso8I1Nla6-MyHaZcbOr7RVYpfTSYRLVEFfxli030RVd1aDfr1y" rel="nofollow" target="_blank">https://investors.vaxart.com</a> for 30 http://www.streetinsider.com/Press+Releases/Vaxart+to+Present+at+the+Oppenheimer+36th+Annual+Healthcare+Life+Sciences+Conference+on+February+25%2C+2026/26018235.html Wed, 18 Feb 2026 08:00:00 -0400 A.42665875 O.14901680 O.20329759 VXRT VXRT